BioCentury | Nov 11, 2016
Company News

Tyg Oncology, Cancer Research UK deal

...to CRUK. Tyg has rights to TYG100, an active S-TIR immunotherapy against gastrin , from OncoQR ML...
BioCentury | Jun 15, 2015
Emerging Company Profile

Maximizing immunogenicity

...Mudde said. "In our case, the greater immunogenicity means the water faucet is completely open." OncoQR's...
...means the frequency of vaccinations can be used to increase or decrease the immunological response. OncoQR...
...immunotherapies, OQR300 and OQR400, in preclinical development against undisclosed, commercially validated cancer targets. Langer said OncoQR...
Items per page:
1 - 2 of 2
BioCentury | Nov 11, 2016
Company News

Tyg Oncology, Cancer Research UK deal

...to CRUK. Tyg has rights to TYG100, an active S-TIR immunotherapy against gastrin , from OncoQR ML...
BioCentury | Jun 15, 2015
Emerging Company Profile

Maximizing immunogenicity

...Mudde said. "In our case, the greater immunogenicity means the water faucet is completely open." OncoQR's...
...means the frequency of vaccinations can be used to increase or decrease the immunological response. OncoQR...
...immunotherapies, OQR300 and OQR400, in preclinical development against undisclosed, commercially validated cancer targets. Langer said OncoQR...
Items per page:
1 - 2 of 2